YOLFTbeta
NewAmsterdam Pharma Company N.V. Ordinary Shares

NewAmsterdam Pharma Company N.V. Ordinary Shares

NAMS · NASDAQ · Healthcare / Biotechnology

20.14USD+0.17 (+0.85%)

Price History

Full chart

Market Stats

Previous Close19.97
Open19.93
Day Range19.48 – 20.62
52-Week Range21.02 – 42.21
Volume1.67M
Market Cap2.76B
P/E (TTM)0.00
Forward P/E119.05
EPS-2.26
Dividend Yield0.00%
Beta0.09
50-Day Avg26.38
200-Day Avg31.46

About

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Michael Harvey Davidson FACC, Facp., M.D.
  • Employees100
  • HeadquartersGooimeer 2-35, Naarden, Netherlands, 1411 DC, USA
  • Websitehttps://www.newamsterdampharma.com

Leadership

  • Dr. Michael Harvey Davidson FACC, Facp., M.D.CEO, President & Executive Director · b. 1956
  • Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.Founder, Chief Scientific Officer, Member of Executive Board & Director · b. 1954
  • Mr. Mayur Amrat SomaiyaChief Financial Officer · b. 1974
  • Mr. Robert W. Gunning C.P.A., CGMAPrincipal Accounting Officer, VP & Controller · b. 1971
  • Mr. Matthew PhilippeExecutive VP & Head of Investor Relations
  • Mr. Michael F. Marino Esq.Chief Legal Officer & Corporate Secretary · b. 1976
  • Mr. Chris DeluzioExecutive Vice President of Sales Enterprise Operations
  • Ms. Maryellen McQuadeChief People Officer
  • Ms. Juliette Audet M.B.A., M.Sc.Chief Strategy & Business Officer · b. 1987
  • Dr. Marc Ditmarsch M.D.Chief Development Officer · b. 1967

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00102.69M14.09M45.56M22.50M
Growth (%)----86.28%+223.37%-50.61%
Cost of Revenue-14.56K70.70K44.39K113.00K59.00K
Gross Profit--14.56K102.69M14.09M45.56M22.44M
Gross Margin--100.00%100.00%100.00%99.74%
Operating Expense-34.96M106.25M197.06M221.85M248.13M
Operating Income-6.63M-34.98M-3.56M-182.97M-176.29M-225.68M
Operating Margin---3.46%-1298.56%-386.91%-1002.90%
EBITDA-6.63M-41.37M-22.34M-176.86M-241.49M-242.32M
EBITDA Margin---21.75%-1255.22%-530.00%-1076.86%
Net Income-7.02M-41.78M-22.63M-176.94M-241.60M-203.82M
Net Income Margin---22.04%-1255.76%-530.25%-905.74%
R&D4.94M28.97M86.74M159.42M151.41M141.83M
R&D as % of Total Revenue--84.47%1131.47%332.30%630.28%
Interest Expense344.00K411.00K287.00K6.80M0-
Interest Expense % of Total Revenue--0.28%48.26%0.00%-

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets139.87M67.99M478.50M347.10M864.62M769.28M
Total Liabilities12.41M11.36M48.43M58.70M107.12M85.85M
Total Equity127.46M56.63M430.07M288.39M757.50M683.43M
Cash1.37M60.38M467.73M340.45M771.74M490.00M
Total Debt11.65M186.51K126.00K60.00K448.00K202.00K
Net Debt-1.37M-60.19M-467.60M-340.39M-771.29M-489.80M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.34M-29.51M10.66M-141.22M-158.56M-147.78M
Investing Cash Flow-15.99K-24.00K-221.00K-24.00K-62.85M-174.92M
Financing Cash Flow13.92M84.70M391.90M8.91M659.51M29.52M
Capital Expenditure15.99K24.00K221.00K24.00K672.00K246.00K
Free Cash Flow-7.36M-29.54M10.44M-141.24M-159.24M-148.03M
FCF to OCF100.22%100.08%97.93%100.02%100.42%100.17%

Earnings

Report DateMay 24, 2021Aug 9, 2021Nov 9, 2021Mar 25, 2022May 12, 2022Aug 11, 2022Oct 18, 2022Mar 31, 2023May 8, 2023Aug 7, 2023Nov 13, 2023Feb 28, 2024May 8, 2024Aug 7, 2024Nov 6, 2024Feb 26, 2025May 8, 2025Aug 6, 2025Nov 5, 2025Feb 18, 2026May 7, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate-------1.14-0.49-0.44-0.42-0.76-0.55-0.48-0.52-0.45-0.96-0.44-0.43-0.38-0.40-0.41-0.48-0.50
EPS Actual0.16-0.070.100.050.08-0.07-0.27-1.80-0.44-1.01-0.56-0.54-0.99-0.38-0.16-0.93-0.30-0.13-0.41-0.63-0.34-0.52-
Surprise------76.38%-267.35%1.11%-140.48%25.76%1.82%-106.25%26.92%64.44%3.13%31.82%69.77%-7.89%-57.50%17.07%-8.33%-
Timing------After-hoursPre-market-Pre-market-After-hoursAfter-hoursPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap2.76B
Enterprise Value2.08B
Trailing P/E0.00
Forward P/E119.05
Price / Sales387.11
Price / Book4.29
EPS-2.26
Book Value5.37
Revenue (TTM)7.12M
Gross Profit (TTM)7.12M
EBITDA-244.16M
Profit Margin0.00%
Operating Margin-1752.61%
Return on Equity-36.81%
Return on Assets-20.11%
Shares Outstanding116.90M
Shares Float81.50M
Beta0.09
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 9 analystsTarget 50.74
  • Strong Buy
    5
  • Buy
    4

Ownership Breakdown

Institutions
106.50%
Insiders
0.90%
Retail / Other
0.00%

Top Institutional Holders

  • Frazier Life Sciences Management, L.P.
    16.94M14.17%
  • Capital World Investors
    12.23M10.23%
  • RA Capital Management, LLC
    9.55M7.99%
  • FCPM III SERVICES BV
    9.20M7.70%
  • FMR Inc
    8.77M7.33%
  • Bain Capital Life Sciences Investors, LLC
    7.31M6.11%
  • Deerfield Management Co
    4.26M3.57%
  • Viking Global Investors LP
    4.20M3.52%
  • Duquesne Family Office LLC
    3.07M2.57%
  • Polar Capital Holdings PLC
    2.83M2.37%
  • HHG PLC
    2.26M1.89%
  • Medicxi Ventures Management (Jersey) Ltd
    2.21M1.85%
  • Maverick Capital Ltd
    2.19M1.83%
  • Jennison Associates LLC
    2.10M1.76%
  • The Goldman Sachs Group Inc
    1.95M1.63%
  • Capital Research & Mgmt Co - Division 3
    1.72M1.44%

Top Fund Holders

  • American Funds SMALLCAP World A
    9.27M7.75%
  • Capital Group Global Equity Canada F
    2.52M2.11%
  • Fidelity Contrafund
    2.33M1.95%
  • Strategic Advisers Fidelity US TtlStk
    2.24M1.87%